Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels

Brain Research

Volumn 910, Issue 1-2, 2001, Pages 182-186

  Trabace, Luigia ^a   Cassano, Tommaso ^a   Cagiano, Raffaele ^a   Tattoli, Maria ^a   Pietra, Claudio ^b   Steardo, Luca ^a   Kendrick, Keith M ^c   Cuomo, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b CHIESI FARMACEUTICI S P A   (Italy)

^c BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

Alzheimer's disease; Amino acid; Anticholinesterase inhibitor; CHF2819; ENA713; Rat hippocampus

Indexed keywords

AMINO ACID; ARGININE; ASPARTIC ACID; CHOLINESTERASE INHIBITOR; CITRULLINE; GANSTIGMINE; GLUTAMIC ACID; NOOTROPIC AGENT; RIVASTIGMINE; TAURINE;

ALZHEIMER DISEASE; AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ALZHEIMER DISEASE; ANIMALS; ARGININE; ASPARTIC ACID; CARBAMATES; CHOLINESTERASE INHIBITORS; CITRULLINE; CYCLIC N-OXIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACIDS; EXTRACELLULAR SPACE; GLUTAMIC ACID; HIPPOCAMPUS; MALE; MICRODIALYSIS; NEURONS; PHENYLCARBAMATES; RATS; RATS, WISTAR; SYNAPTIC TRANSMISSION; TAURINE;

EID: 0035839230     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)02653-1     Document Type: Article

References (22)

1. Therapeutic strategies in Alzheimer's disease
2. CSF excitatory amino acids and severity of illness in Alzheimer's disease
3. Alzheimer's disease: From the cholinergic hypothesis to cholinergic treatment
4. Neurochemical aspects of dementia disorders
5. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type
6. Effects of metrifonate on memory impairment and cholinergic dysfunction in rats
7. Formation of olfactory memories mediated by nitric oxide
8. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
9. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats
10. Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease
11. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease
12. Brain banks and research in neurochemistry
13. Glutamate dysfunction in Alzheimer's disease: An hypothesis
14. Possible roles of taurine as membrane stabilizer; modulating effects on release of neurotransmitters and transport of calcium in excitable tissues
15. Glutamate receptors: Brain function and signal transduction
16. The effect of cholinesterase inhibitors studied with brain imaging
17. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
18. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease
19. Neurodegenerative disorders: The role of peroxynitrite
20. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease
21. In vivo neurochemical effects of acetylcholinesterase inhibitor ENA713 in rat hippocampus